Literature DB >> 29305286

Clinical Outcomes of Osteochondral Allograft Transplantation for Secondary Treatment of Osteochondritis Dissecans of the Knee in Skeletally Mature Patients.

Eric J Cotter1, Rachel M Frank1, Kevin C Wang1, Trifon Totlis2, Sarah Poland1, Maximillian A Meyer1, Brian J Cole3.   

Abstract

PURPOSE: To report clinical outcomes of osteochondral allograft transplantation (OCA) for skeletally mature patients with osteochondritis dissecans (OCD) lesions of the knee in whom prior surgical intervention has failed, and to describe return-to-sport (RTS) rates and any predictive demographic or preoperative variables associated with a higher likelihood to RTS.
METHODS: Patients who underwent OCA by a single surgeon (B.J.C.) between October 1, 2002, and November 30, 2014, for a diagnosis of OCD with a minimum of 2 years' follow-up were included. Demographic, surgical history, operative, and postoperative data points including RTS were analyzed for all patients collectively, with subanalysis to identify any demographic and operative variables associated with the ability to RTS. Failure was defined as revision OCA, gross appearance of graft failure on second-look arthroscopy, or conversion to arthroplasty.
RESULTS: We identified 41 consecutive patients (43 knees), with 37 patients (39 knees, comprising 26 male and 13 female knees) available for clinical follow-up at an average of 7.29 ± 3.30 years. There was significant improvement (P < .05) in all patient-reported outcome scores, with the exception of the Short Form 12 mental subscale (P = .910). Most patients (81.6%) reported being either mostly satisfied or completely satisfied at final follow-up. Of patients self-identifying as athletes preoperatively (n = 22), 18 (81.8%) achieved RTS at an average of 14.0 ± 8.7 months. Athletes with failure to RTS had a significantly greater body mass index (RTS, 24.68 ± 3.67; no RTS, 27.82 ± 0.69; P = .005). Subsequent surgery was performed in 14 patients (35.9%), and primary OCA failed in 2 patients at an average of 6.2 ± 3.8 years.
CONCLUSIONS: OCA is a successful secondary surgical treatment for OCD of the knee in skeletally mature patients and leads to clinically meaningful improvements in patient-reported outcome scores and high patient satisfaction and RTS rates in low-level athletes at an average of 7.29 years' follow-up. Athletes with failure to RTS were found to have a significantly higher body mass index. Although reoperation may be common after OCA (35.9%), the failure rate is low (5.1%) in this series. LEVEL OF EVIDENCE: Level IV, case series.
Copyright © 2017 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29305286     DOI: 10.1016/j.arthro.2017.10.043

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  14 in total

1.  Clinical Outcomes after Revision of Autologous Chondrocyte Implantation to Osteochondral Allograft Transplantation for Large Chondral Defects: A Comparative Matched-Group Analysis.

Authors:  Gergo Merkely; Takahiro Ogura; Jakob Ackermann; Alexandre Barbieri Mestriner; Andreas H Gomoll
Journal:  Cartilage       Date:  2019-03-22       Impact factor: 4.634

Review 2.  Treatment of unstable knee osteochondritis dissecans in the young adult: results and limitations of surgical strategies-The advantages of allografts to address an osteochondral challenge.

Authors:  Giuseppe Filardo; Luca Andriolo; Francesc Soler; Massimo Berruto; Paolo Ferrua; Peter Verdonk; Frederic Rongieras; Dennis C Crawford
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2018-12-06       Impact factor: 4.342

3.  Does Flipping the Tubercle for Improved Cartilage Repair Exposure Increase the Risk for Arthrofibrosis?

Authors:  Gergo Merkely; Jakob Ackermann; Emily Sheehy; Andreas H Gomoll
Journal:  Cartilage       Date:  2020-10-23       Impact factor: 3.117

Review 4.  Osteochondral Allografts for Large Osteochondral Lesions of the Knee Joint: Indications, Surgical Techniques and Results.

Authors:  E Carlos Rodriguez-Merchan; Carlos A Encinas-Ullan; Alexander D Liddle
Journal:  Arch Bone Jt Surg       Date:  2022-03

Review 5.  Osteochondritis Dissecans: Current Understanding of Epidemiology, Etiology, Management, and Outcomes.

Authors:  Michael M Chau; Mikhail A Klimstra; Kelsey L Wise; Jutta M Ellermann; Ferenc Tóth; Cathy S Carlson; Bradley J Nelson; Marc A Tompkins
Journal:  J Bone Joint Surg Am       Date:  2021-06-16       Impact factor: 6.558

6.  The cost-effectiveness of osteochondral allograft transplantation in the knee.

Authors:  Hema Mistry; Andrew Metcalfe; Nick Smith; Emma Loveman; Jill Colquitt; Pamela Royle; Norman Waugh
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-02-05       Impact factor: 4.342

7.  Health State Utilities in Children and Adolescents With Osteochondritis Dissecans of the Knee.

Authors:  Joshua Adjei; Benedict U Nwachukwu; Yi Zhang; Huong T Do; Daniel W Green; Emily R Dodwell; Peter D Fabricant
Journal:  Orthop J Sports Med       Date:  2019-12-05

8.  Contralateral Lateral Femoral Condyle Allografts Provide an Acceptable Surface Match for Simulated Classic Osteochondritis Dissecans Lesions of the Medial Femoral Condyle.

Authors:  Nabeel Salka; John A Grant
Journal:  Orthop J Sports Med       Date:  2020-01-28

9.  The Role of Hypertension in Cartilage Restoration: Increased Failure Rate After Autologous Chondrocyte Implantation but Not After Osteochondral Allograft Transplantation.

Authors:  Gergo Merkely; Jakob Ackermann; Andreas H Gomoll
Journal:  Cartilage       Date:  2020-01-22       Impact factor: 3.117

10.  Metrics of OsteoChondral Allografts (MOCA) Group Consensus Statements on the Use of Viable Osteochondral Allograft.

Authors:  Simon Görtz; Suzanne M Tabbaa; Deryk G Jones; John D Polousky; Dennis C Crawford; William D Bugbee; Brian J Cole; Jack Farr; James E Fleischli; Alan Getgood; Andreas H Gomoll; Allan E Gross; Aaron J Krych; Christian Lattermann; Bert R Mandelbaum; Peter R Mandt; Raffy Mirzayan; Timothy S Mologne; Matthew T Provencher; Scott A Rodeo; Oleg Safir; Eric D Strauss; Christopher J Wahl; Riley J Williams; Adam B Yanke
Journal:  Orthop J Sports Med       Date:  2021-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.